| Name | Title | Contact Details |
|---|
Tute Genomics is a web-based, powerful solution for analyzing genetic sequencing data in a matter of minutes. Tute is robust, secure, professional-grade; a true web application that lives in the cloud and has the ability to analyze and annotate entire human genomes in a rapid and cost-effective way. What makes Tute stand out above the rest? Tute is built on ANNOVAR, the gold-standard in whole genome interpretation with already over 400 scientific citations. Tute pulls in 125+ annotation types, databases, and scores; more than any other analyses software. Tute can use your genome variant data in a variety of common formats (VCF, CG masterVar, and more) and uses proprietary machine-learning algorithms to rank each variant. For each genetic variant, Tute presents a human-readable annotation with links to external supporting evidence. Tute supports disease gene finding, biomarker discovery, pharmacogenetics and more.
Code Bio was founded on the belief that more can be done for people living with debilitating genetic diseases. We are driven by the potential of our transformative technology to treat the untreatable and cure the incurable. Code Bio is developing highly targeted genetic medicines with its proprietary, novel, multivalent, synthetic DNA delivery platform, 3DNA®, which has been engineered to overcome many of the challenges inherent with the delivery of genetic medicines. 3DNA offers unparalleled tissue and cell targeting specificity, improved bioavailability, capability to deliver large genetic payloads, potential ability to re-dose, and a scalable, modular, reproducible manufacturing process. Our 3DNA delivery platform is poised to transform the field of genetic medicines, enabling targeted delivery of gene therapy, RNAi and other genetic modalities. Currently we are advancing an internal pipeline of genetic medicines focused on select diseases without a cure (Duchenne`s Muscular Dystrophy and Type 1 Diabetes), as well as establishing partnerships to take forward programs in both rare and prevalent diseases.
Ignyta, located in San Diego, California, is a biotechnology company developing precision medicine with integrated Rx/Dx solutions for cancer patients. Its goal is to discover and develop revolutionary new drugs that target activated genes in cancer cells for the customized treatment of cancer patients. The company's present focus is on the development of RXDX-101, its proprietary oral tyrosine kinase inhibitor that targets solid tumor indications, and advancing its novel Spark discovery programs that leverage its proprietary cancer genomic and epigenomic knowledge bases
ZYTO Corporation is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Anox Kaldnes Inc is a Providence, RI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.